Moshe Levin

Medial EarlySign develops machine learning based decision support tools that expose the hidden layer of information in standard medical data. These new insights enable personal and outcome-based interpretation of medical data, yielding individualized predictions and treatment options for each patient, as well as early prediction of life-threatening conditions. Our cutting edge tools are designed to offer healthcare organizations a new way of looking at their data, empowering them with proactive, personalized and predictive care management capabilities. Medial EarlySign built and refined a unique algorithmic platform designed to handle large medical data and billions of medical data elements. Our validated algo-medical platform creates thousands of parameters based on existing medical data, analyzing trends and interrelationships over time. This enables setting personalized risk levels for mass populations in moments, and identifying individuals who may require further intervention. Our solutions go through rigorous clinical validation. The company is currently conducting clinical trials in 14 leading research institutions around the world totaling more than 5 million patients.

RADWIN is a leading provider of Point-to-Multipoint and Point-to-Point broadband wireless solutions. Incorporating the most advanced technologies such as a Beam-forming antenna and an innovative Air Interface, RADWIN’s systems deliver optimal performance in the toughest conditions including high interference and obstructed line-of-sight. Deployed in over 170 countries, RADWIN’s solutions power applications including backhaul, broadband access, private network connectivity, video surveillance transmission as well as delivering broadband on the move for trains, vehicles and vessels.

Medial EarlySign develops machine learning based decision support tools that expose the hidden layer of information in standard medical data. These new insights enable personal and outcome-based interpretation of medical data, yielding individualized predictions and treatment options for each patient, as well as early prediction of life-threatening conditions. Our cutting edge tools are designed to offer healthcare organizations a new way of looking at their data, empowering them with proactive, personalized and predictive care management capabilities. Medial EarlySign built and refined a unique algorithmic platform designed to handle large medical data and billions of medical data elements. Our validated algo-medical platform creates thousands of parameters based on existing medical data, analyzing trends and interrelationships over time. This enables setting personalized risk levels for mass populations in moments, and identifying individuals who may require further intervention. Our solutions go through rigorous clinical validation. The company is currently conducting clinical trials in 14 leading research institutions around the world totaling more than 5 million patients.